Aktuellt
SENASTE
Redeye revisits Immunicum’s investment case, as the company stands on the brink of exciting developments, with two phase II assets in its pipeline and many shots on goal to drive DCP-001 and ilixadencel toward pivotal trials. We believe the share trades at a depressed valuation at present, with a potential re-rating on the cards in the next six months.
LÄS MER
